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In vivo release study
A B S T R A C T
Sustained release of active interferon-α (IFN-α) has been achieved from core-shell nanoparticles (NPs) prepared
by aqueous precipitation of IFN-α-enriched human serum albumin (HSA-IFN-α) and layer-by-layer (L-b-L) by
coating of the IFN-α NPs with poly(sodium-4-styrene) sulphonate (PSS) and chitosan (Chit). The concentration
and the pH of HSA solution were optimized during the development of this method. Dynamic light scattering
(DLS), zeta-potential, thermal analysis (differential scanning calorimetry (DSC) and termogravimetry (TG)), X-
ray diffraction (XRD), IFN-α activity and morphology (transmission electron microscope (TEM)) studies were
used to control the preparation and analyse the products. The dissolution kinetics of NPs was measured in vitro
over 7 days in Hanson dissolution tester with Millex membrane. In vivo studies in Pannon white rabbit detected
steady IFN-α plasma level for 10 days after subcutaneous injection administration of the HSA-IFN-α NPs. The
IFN-α plasma concentration was detected by using the enzyme-linked immunosorbent assay (ELISA) method. In
the present paper we discuss the preparation method, the optimization steps and the results of in vitro and in
vivo release studies. It was established that 76.13% HSA-IFN-α are encapsulated in the core-shell NPs.
1. Introduction
Interferons (IFNs) are cytokines that regulate the expression of
genes determining cellular fate and anti-viral defense. IFN-α and IFN-β
represent class I IFNs. IFN-γ defines class II IFN. Class III (λ-IFNs) exerts
biological properties reminiscent of that of IFN-α and IFN-β (Pollok
et al., 2013). IFNs can be considered as an effective adjuvant treatment
for selected melanoma patients, although more refined algorithms are
required to optimize its effectiveness (Di Trolio et al., 2015).
Drug formulation studies are centred around the spatial and kinetic
control of drug release. Core–shell particles have become an important
research area over past decades due to their great application potentials
in fields like bio-imaging, controlled release, tumour therapy, tissue
engineering, and so forth (Chen et al., 2010; Gao et al., 2013; Giri1
et al., 2011; He et al., 2015; Khdair et al., 2016; Lei et al., 2014; Li et al.,
2018; Narayanan et al., 2014; Nie et al., 2010a; Nie et al., 2010b;
Sedeky et al., 2018; Yang et al., 2013; Wang et al., 2012; Wu et al.,
2011). Among the various formulation possibilities colloidal methods
provide the largest variability regarding particle size, pore structure,
solvation and charge properties of the surface, pH- and ionic strength
dependence of specific functional groups (Zashikhina et al., 2017).
Exploiting self-ordering and self-organizing properties of colloids, more
complex structures can also be prepared. One of the smart colloidal
drug carrier formulations is layer-by-layer (L-b-L) construction of
multiple molecular sheets at surfaces of colloidal nano and micro-
particles (Borkovec and Papastavrou, 2008; Kotov et al., 1995;
Martinek et al., 2006; Möhwald, 2000; Radtchenko et al., 2000;
Sukhorukov et al., 1998; Zhao et al, 2018). This method, worked out
originally for preparation of multilayered nanostructures on flat mac-
roscopic or colloidal surfaces, is also called electrostatic self-assembly
(ESA). The multilayered polyelectrolyte coatings serve as membranes,
the designed pores of which can entrap or transmit drug molecules, or
to retard their diffusion. Various types of polyelectrolyte multilayers
have been prepared on the surface of microscopic particles
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(Balabushevitch et al., 2001; Caruso et al., 2000; Freag et al., 2018; Ke
et al, 2018), but NP coating by L-b-L shells is rare in the literature. Soft
larger particles or small particles with thick soft coating are also able to
penetrate endothelia. In addition, some injectable formulations for
sustained release also need to be prepared from nanoscale particle
dispersions. The duration of sustained drug release from the nano or
microcarrier systems is usually not longer than several tens of hours (de
Villiers et al., 2011).
Microparticles are frequently used to prepare capsules into which
drug molecules can be filled in a separate infiltration step. The poly-
electrolyte layers are permeable and various drug molecules can be
infiltrated into the capsules via simple diffusion process. H. Möhwald
and co-workers prepared micrometer-sized (10 µm diameter) enzyme
crystals coated with polyelectrolyte multilayers (Balabushevitch et al.,
2001; Caruso et al., 2000), and the enzyme retained biological activity.
Polyelectrolyte microcapsules were also formed on melamine for-
maldehyde microparticles, for subsequent infiltration of active agents
(Ai et al., 2005).
For several years, large molecules such as proteins were not con-
sidered applicable for controlled release systems, because they are too
large to diffuse through most polymeric materials (Dai et al., 2005;
Sinha and Trehan, 2003; Yu et al., 2016). After the breakdown of this
presumption many polymers have been used as delivery vehicles for
insulin, growth factors, angiogenesis inhibitor proteins or protein ki-
nase C inhibitor (Liu et al, 2019; Shkodra-Pula et al., 2019). Proteins
are very sensitive to environmental conditions. Changes in pH, tem-
perature, salinity, or the presence of complexing agents or cosolvents
can easily lead to denaturation and inactivation (Kim et al., 2015).
Protein microparticles have also been prepared by the emulsion or
double emulsion method (Duncana et al., 2005). Core-shell structured
protein microparticles resulted also in the adsorption of a protein active
agent on porous CaCO3 particles (Volodkin et al., 2004) coated subse-
quently with polyelectrolytes, after which the inorganic template was
extracted. The dissolution of the template risks protein denaturation. In
the case of microcapsules, the protein must be loaded into the emptied
capsules, but the efficiency of infiltration is usually very low. Jörgensen
et al. (2006) analysed the methods of protein formulations (micro-
spheres, emulsions, hydrogel based macroparticles) and revealed that
many important questions such as formulation stability, complete drug
release, shelf stability, are not yet resolved.
In the present work, protein NPs were prepared for sustained release
of IFN-α. Nowadays, the administration route of IFN-α is frequent in-
jection of the dissolved protein, because it is a very sensitive material.
The frequent injections have disadvantages such as low patient com-
pliance because of the pain they cause. One of the solutions can be the
application of oral delivery of the IFN-α (as a chemotherapeutic agent)
(Caldorera-Moore et al., 2019). Patient compliance can also be in-
creased with application of sustained release injection, for which the
administration frequency is considerably lower. The solid core of the
NPs was prepared by precipitation of HSA-IFN-α with salt. The NPs
were subsequently coated by polyelectrolyte multilayers using the ESA
method, or L-b-L self-assembly.
In our previous study bovine serum albumin (BSA) based core–shell
NPs were developed as carrier systems for drug transportation. At
pH=3, the oppositely charged polyelectrolytes: poly(sodium-4-
styrene) sulphonate (PSS) and the chitosan (Chit) was bound to the
positively charged protein via electrostatic interactions. Ibuprofen was
applied as model molecule which has low solubility (Varga et al.,
2014). The aim of our work is to achieve sustained IFN-α release for
10 days after injection and test it in animal trials.
2. Materials
Human serum albumin (HSA) (Trigon Biotechnology Rt., Hungary)
with isoelectric point, pHiep= 4.8 (Müller et al., 2004), as model pro-
tein and, human serum albumin enriched in recombinant human
interferon-α (HSA-IFN-α) (Trigon Biotechnology Rt., Hungary) were
obtained as solutions in phosphate buffer (PBS, pH=6.8) from Trigon
Biotechnology Rt. (Hungary), and used without further purification.
Poly(sodium-4-styrenesulphonate) (PSS) (Mw=70,000 Da) (Sigma-
Aldrich), low molecular weight chitosan (Chit) (DD > 75%, Brookfield
viscosity 20.000 cps) (Sigma-Aldrich), acetic acid (Molar Chemicals,
Hungary) and the precipitating salt Na2SO4 (Sigma-Aldrich) were used
without further purification. Ultrapure water was used throughout the
experiments (MilliQ RG system, Millipore), and all the solutions were
filtered through Millipore syringe filters of 0.22 μm pore diameter be-
fore use. For the determination of protein concentration in the aliquot
after dissolution test Bicinchonic Acid Kit (Sigma-Aldrich) was used.
3. Methods
3.1. Preparation of core-shell NPs
First step of the core-shell NP preparation was the precipitation of
HSA-IFN-α from its buffered solution. The bare NPs should retain their
IFN-α content and HSA solubility in order to release the IFN-α on ad-
ministration. To satisfy these requirements, we applied the method of
salting out by using multivalent ions. The mechanism of globular HSA
precipitation by multivalent ions is basically charge screening and/or
bridging through the multivalent ion. The electrokinetic potential of the
precipitated particles reveals, which of them is effective. In the charge
screening mechanism, the particle charge must reverse, or at least get
neutralized, depending on the valence of the coagulating ion. On the
other hand, bridging does not require complete neutralization. Specific
effects, leading to the Hoffmeister series salting in and salting out ef-
fects, also play a role (Shih et al., 1992; Shiau and Chen, 1997).
The control parameters of the NP synthesis were: precipitation ef-
ficiency, average particle size, electrokinetic potential of the particles,
and dissolution efficiency on dilution. Below the isoelectric point of
HSA (pH≤ 4.8), sulphate anions were used as effective precipitating
ions in the form of saturated sodium salt. We have observed the for-
mation of HSA NPs using Na2SO4, but not with two-valent cations.
Hydrolysing cations did not precipitate HSA, since negatively charged
metal hydroxides formed at high pH, which could not bind the also
negatively charged HSA.
NPs containing HSA and HSA-IFN-α were prepared. During the
preparation the first step was the protein precipitation with Na2SO4
solution. 15ml of HSA solution at 3.9 w/v % concentration was acid-
ified to pH=3 with acetic acid and precipitated with 3ml of Na2SO4
solution of 2M concentration. The resulting particles were separated by
centrifuging in a Hettich Universal 30F (Hettich FurnTech GmbH,
Germany) table top centrifuge. The second main step was the pre-
paration of the layers (PSS/Chit/PSS). After optimization, the PSS and
Chit concentrations were chosen as 0.3 w/v % and the pH was set to 3
by acetic acid. The precipitated HSA-IFN-α was redispersed in 10ml of
the polyelectrolyte solutions followed by continuous stirring for 1 h.
The samples were centrifuged after each polyelectrolyte layer binding
step. Method procedure is presented schematically in Fig. 1. Each step
of the process was accompanied by a series of quality control analyses
(supernatant HSA concentration, DLS, and zeta potential determina-
tion). Finally, the HSA-IFN-α core-shell NPs were lyophilized.
3.2. Optimization of the precipitation conditions of HSA
For NPs preparations, the mild wet sol-gel method and the elec-
trostatic adsorption mechanism were exploited. The precipitation ki-
netics was measured by using transmission spectroscopy at λ=700 nm
(Carl Zeiss photometer, Jena, Germany), and for salt dosing a Radelkis
OP-930 Autoburette (Radelkis, Hungary) was used. The volume of the
precipitating Na2SO4 solution of 2M had been optimized. The HSA
concentration was 3.9 w/v % and the volume was 15ml.
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3.3. Investigation of HSA precipitation efficiency with UV-VIS spectroscopy
In the course of precipitation, the concentration of HSA was mea-
sured in the supernatant after centrifugation with UV-VIS spectroscopy
at pHs 2.7, 2.8, 2.9 and 3. The HSA concentration of the supernatants
was also measured by UV-VIS spectroscopy after each steps of poly-
electrolyte multilayer build-up. HSA has an absorption peak at 278 nm,
and PSS at 260 nm. The calibrations are measured both at λ=278 and
260 nm for each solute to obtain the actual extinction coefficients (ε).
The concentrations of HSA in the supernatants were calculated.
3.4. Zeta-potential and dynamic light scattering measurements
The particles were characterized by the particle size distribution
from dynamic light scattering (DLS) measurements and by the elec-
trokinetic potential from zeta potential (ζ) measurements in a Malvern
Zetasizer Nano ZS apparatus (Malvern Instruments Ltd., UK). The zeta
potential of the HSA NPs was positive, suggesting that the particles are
formed primarily due to sulphate anion bridging thus the original po-
sitive electrokinetic potential of the dissolved protein molecules is re-
tained. This condition is optimal for the electrostatic adsorption of
anionic polyelectrolyte PSS. The HSA NPs are prepared at pH=3. At
the low pH only strong polyelectrolytes are fully dissociated, and PSS
had been chosen for the core-shell NPs preparation for this reason. For
optimization of PSS coating, the concentration of PSS solutions were
between 0.0005 and 1 w/v % and the pH was set to 3 by acetic acid.
3.5. Measurement of streaming potential
Particle charged detector (Mütek PCD-03, BTG Mütek GmbH,
Germany) was used to measure the equivalence point of charge reversal
of PSS coated NPs during titration with Chit. The concentration of Chit
solutions was between 0.005 and 0.5 w/v % and the pH was also set to
3 by acetic acid.
3.6. Characterization of the HSA-IFN-α core-shell NPs
3.6.1. Calculation of encapsulation efficiency (EE%) and the loading
capacity (LC%)
Encapsulation efficiency was calculated from the UV spectra of the
supernatant after every centrifugation step during preparation.
Encapsulation efficiency (EE%) by the adsorptions of PSS and Chit on
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Differential scanning calorimetry (DSC) and termogravimetric (TG)
(Mettler Toledo TGA/SDTA 851e and DSC 822e) analysis was used for
the experiments. The temperature interval was 25–300 °C, and the
heating rate was 4 °C/min.
3.6.3. X-ray diffraction (XRD)
The degree of crystallinity of the freeze dried powder samples was
Fig. 1. Preparation scheme of the HSA-IFN-α core-shell NPs.
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checked by application of x-ray diffractometer (Philips PW 1830
Diffractometer) using Kα radiation at a voltage of 40 kV and a current
of 35mA.
3.6.4. Transmission electron microscopy (TEM)
The particle size and shape was also inspected by using transmission
electron microscopy (TEM, Philips CM-10).
3.7. In vitro antiviral activity measurement
In vitro antiviral activity of IFN-α released from the HSA-IFN-α NPs
was measured using WISH tissue culture, Vesicular Stomatitis virus and
NIH, Ga23-902-530 Hu IFN-α standard. The antiviral activity of the
original HSA-IFN-α was measured between 1.63*105-1.92*105 IU/mg.
As the effective IFN-α content cannot be measured in the final core-
shell NPs therefore the antiviral activity was determined.
3.8. In vitro dissolution study
Hanson Research SR8-Plus Dissolution Test Station (Hanson Reserch
Corporation, USA), was used for the in vitro dissolution study. Millex
GP 0.22 membrane (Merck Millipore, Dublin, Ireland) was applied for
the separation of encapsulated IFN-α in NP dispersion. The mixing was
continuous at 100 rpm. The dissolution media was 50ml PBS (phos-
phate buffer solution, pH=6.8) at 36 °C. The duration was 144 h
(6 day). On the first day, 1ml aliquots were taken every 30min in the
course of 2 h, then once in 4 h. Next 3 days aliquots were taken five
times then on the 6th day once (144 h). The volumes of the aliquots
were refilled with PBS after each samplings. There were 6 parallel
measurements. The protein concentration in the aliquots were de-
termined by Bicinchoninic Acid Kit (Sigma-Aldrich) and by UV-VIS
spectrophotometry (Helios α, Unicam Spectronic, UK) at 562 nm.
For the interpretation of dissolution model, the Sigma Plot 12.0 for
Windows (Systat Software, Inc.) software was applied. The correlation
coefficients (R2), the rate constant (k) and the release exponent (n) of
models were calculated. The Korsmeyer–Peppas model, a semiempirical
model that can be used to analyze data on drug release from polymers
(Peppas, 1985), implies that the fractional release of drug is ex-
ponentially related to the release time, i.e., a power law equation: Eq.
(3). The mathematical model used to fit this profile was the Korsmeyer-
Peppas or power low model equation by Sigma Plot 12.0 for Windows.
In the case of first order model the drug activity within the reservoir is
assumed to decline exponentially and the release rate is proportional to
the residual activity: Eq. (4).
=∞Mt M ktKorsmeyer - Peppas\;model: / n (3)
∞ = − −Mt M exp ktFirst\;order\;model: / 1 ( ) (4)
where Mt/M∞ is a fraction of drug released at time t, k is the rate
constant, and n is the release exponent (Table 1).
3.9. In vivo study
In vivo IFN-α blood levels were determined in rabbits after sub-
cutaneous administration of the drug formulations to Pannon white
rabbits, using the human IFN-α ELISA kit (BMS216CE) of Bender
MedSystems (Wien, Austria), according to the procedure given by the
producer. Following the administration of IFN-α, blood samples were
taken from the rabbits daily and the IFN-α level was determined.
Egiferon 3⋅106 IU injection was used as control, which contains the
same HSA-IFN-α preparation as the starting material for NP formula-
tions. The mean residence time (MRT) (Eq. (5)) and the elimination








where AUMC is the area under the first moment curve or the curve of
concentration*time versus time, and AUC is the area under the con-
centration versus time curve
= ∗t MRTln 21/2 (6)
4. Results and discussion
4.1. Optimization of the precipitation conditions of HSA
The conditions of precipitation by Na2SO4 were optimized as fol-
lows. The volume of 2M Na2SO4 solution was varied between 0.3 and
3ml, leading to final concentrations between 0.06 and 0.4M. The time
of precipitation decreased from 130min to 9min, and the precipitation
efficiency increased from 40 to 96% with increasing total amount of
Na2SO4 (Fig. 2). However, independent of the above variables, the
particle size was 10 ± 5 nm as obtained from number distribution in
DLS measurements and the ζ potential was +15 ± 5mV in all ex-
periments. 3 ml of 2M Na2SO4 was chosen for further experiments.
pH of the HSA solution was set to pH between 2.7 and 3, using
acetic acid. pH 3 was chosen because the too low pH can cause a de-
crease in enzyme activity and a change in the structure of the protein.
Under pH 2.7 the protein is in a fully extended form (E) (Kun et al.,
2009; Varga et al., 2016). The i.e. p. is around pH 4.7, therefore the
selected pH must be lower than this value because in this range the
charge of albumin is positive and higher than pH 2.7. Therefore the
potential pH was between 2.7 and 4.7. After the measurement of the UV
spectra of the supernatant (Fig. 3), the efficiency of precipitation was
calculated and it can be seen in the case of pH 3 this value was higher
than 60% (61. 31%). Therefore it can be an optimal pH because the
HSA is not in E (extended) form and the precipitation efficiency is still
acceptable.
The set of precipitation optimization experiments led to the fol-
lowing optimal conditions of HSA nanoparticle precipitation, which we
applied also for precipitation of HSA-IFN-α:
pH=3, set by acetic acid solution,
concentration of HSA-IFN-α, cHSA= 3.9 w/v,
concentration of added Na2SO4, cNa2SO4,0= 2M and
Table 1
Characterization of Exponent of Korsmeyer–Peppas Equation (Kelemen,
2012; Korbely et al., 2012).
Release exponent (n) Drug transport mechanism
0.5 Fickian diffusion
0.5 < n < 1 Non-Fickian transport
1 Case II transport
n > 1 Super case II transport
Fig. 2. Changes in the transmittance (T) of HSA solutions in the course of
precipitation using Na2SO4 (10ml, pH=3; 3.9 w/v % HSA; 2M Na2SO4) as
function of time at various Na2SO4 final concentrations.
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final concentration of Na2SO4, cNa2SO4,f = 0.33M.
4.2. Optimization of the concentration and amount of polyelectrolytes for
HSA NP coating
UV–VIS spectrophotometry was used to determine the appropriate
amount of PSS to coat quantitatively the preformed HSA NPs. Excess
amount of free PSS in the supernatant of PSS-coated HSA NP disper-
sions appears in the spectra as a peak at 260 nm and that of HSA at
278 nm. The UV–VIS spectrophotometry results (Fig. 4.) show that the
HSA peak disappears gradually and the PSS peak appears with in-
creasing PSS addition to the dispersion of precipitated HSA NPs
(v= 10ml, cHSA= 3.9 w/v %). All HSA in the dispersion becomes
buried under the PSS shell and settled out with centrifuging at PSS
concentrations between 0.05 and 0.5 w/v %, therefore, its optimal
concentration is found within this range. The adsorption of PSS results
in charge reversal, seen in Fig. 5 as a sharp change of the zeta potential
from +20 to –50mV in a narrow PSS concentration range, accom-
panied by the sharp increase in the particle diameter to ~10 to
~100 nm. Based on the particle size and zeta potential experiments the
necessary amount of PSS for HSA coating under the given conditions
(i.e., volume and pH of the HSA NP dispersion, HSA concentration and
precipitation conditions) is 0.25 w/v %.
Cationic Chit is adsorbed subsequently on the anionic PSS coated
HSA NPs at pH=3, to form the HSA/PSS/Chit NPs. The Chit con-
centration necessary to surface saturation and overcharge the HSA/PSS
particles in 3 w/v % dispersion was ~0.3 w/v % as obtained from PCD
potential measurements demonstrated in Fig. 6.
4.3. Characterisation of NPs
The final HSA recovery after the nanoparticle precipitation and PSS-
coating was obtained from the analysis of UV-VIS spectra of the su-
pernatants after each centrifugation step. After the precipitation step
the yield was 60%. On average, the encapsulation efficiency HSA-IFN-α
core-shell NPs that retained 49.1% of the original amount of HSA-IFN-
α. The procedures applied are small-scale laboratory production
methods with relatively large loss percentage, meaning that scaling up
to industrial size could result in higher encapsulation efficiency.
Knowing the concentration values and the volume of solutions the
amount of HSA-IFN-α content was the differences between the original
and equilibrium data. The difference of these data and the total amount
of HSA-IFN-α (585mg) was the total entrapped HSA-IFN-α amount:
287mg. Encapsulation efficiency (EE%) by the adsorptions of PSS and
Chit on the HSA-IFN-α composite was calculated according to the fol-
lowing equation (Eq. (1)):
= ∗ =
−EE% 100 49.1%mg mgmg
(585 298 )
585
The HSA-IFN-α /polyelectrolyte (PSS/Chit/PSS) ratio was 287mg/
90mg=3.19. This value is very high because of the high amount of
HSA applied as carrier.






mg entrapped HSA IFN α
mg polyelectrolyte mg entrapped HSA IFNα
%
287 ( )
90 ( ) 287 ( )
100
76.13%
This 76.13% relates to the total HSA-IFN-α content of the core–shell
NPs.
Figs. 7 and 8 give a representative example of changing the particle
size distribution and zeta potential of the particles in the process of L-b-
L coating with anionic and cationic polyelectrolyte layers starting from
the bare HSA nanoparticle.
It is clearly seen in Fig. 7 that the hydrodynamic diameter of the
Fig. 3. Absorption spectra of HSA in the supernatant of HSA NPs precipitated
by Na2SO4 (2ml solution of 2M concentration) at different pHs as measured
after centrifugation.
Fig. 4. The absorption spectra of a HSA Np dispersion supernatant after cen-
trifugation as measured at different concentration of added PSS (volume of
dispersion is 10ml, pH=3, HSA precipitated with Na2SO4 solution).
Fig. 5. Changes in zeta potential and hydrodynamic diameter of precipitated
HSA NPs after with increasing concentration of added PSS at pH=3 and HSA
concentration of 3 w/v %
Fig. 6. Streaming potential change of the original HSA/PSS NPs during titration
with chitosan solution at pH=3, as measured by using Particle Charged
Detector instrument (PSS at pH=3 and HSA/PSS concentration of 3 w/v %).
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originally precipitated bare HSA NPs is around 10 nm, and the size
increases stepwise with building up of subsequent layers of the poly-
electrolyte shell. The diameter of the final particle type applicable for
preparation of sustained release IFN-α formulation (i.e., HSA-IFN-α
core-shell NP) is almost one micrometer; but as the shell around the
solid core is flexible the particles can be expected to diffuse in the
smaller capillaries despite of their larger size. The effective build-up of
the alternate polyelectrolyte layers is proven unambiguously by the
alternate positive and negative values of the zeta potential (Fig. 8).
The thermal stability of components and HSA core-shell NPs was
investigated with TG (not shown here) and DSC. The adsorbed water
evaporated from the precipitated HSA and the HSA-IFN-α core-shell
NPs at lower temperature (50–70 °C) than from the lyophilized HSA
(95 °C) (Fig. 9). In the case of the lyophilized HSA there was an en-
dothermic peak at 220 °C, which can be due to melting, structural water
evaporation or thermal decomposition. For the precipitated HSA and
the HSA-IFN-α core-shell NPs, this peak was shifted to higher
temperatures and the rate was decreased that can be explained by in-
creased thermal stability.
XRD patterns of lyophilized HSA, precipitated HSA and the HSA-
IFN-α core-shell NPs (Fig. 10.) reveal the changes in HSA crystallinity in
the course of the preparation procedures. The highly crystalline form of
the lyophilized sample shows a pronounced peak at 2 Θ ~32°, which
decreases significantly in the process of precipitation (precipitated
HSA). This decrease can also be due to the small particle size, as NPs, in
general, have lower degree of crystallinity as compared to macroscopic
phases of the same material. Encapsulation the precipitated protein
renders it fully amorphous. Crystalline form of the salt Na2SO4 used for
the HSA precipitation was not observed in the formulations as the
specific salt peaks are absent in the HSA diffraction curves.
The morphology and the layered structure around the HSA-IFN-α
core-shell NPs can be seen in Fig. 11. The pictures in panels (a) and (b)
were obtained at different the focus positions in depth and reveal dif-
ferent views of the same particles. This type of focus sensitivity is
generally not seen for solid particles. On the other hand, the differences
in the electron density of precipitated (probably crystalline, as seen
from XRD results) HSA and layered (probably non-crystalline) poly-
electrolyte nanophases can explain the observed focus-sensitivity of the
HSA-IFN core-shell NPs.
4.4. Antiviral activity
Antiviral activity of the HSA-IFN-α was determined in WISH tissue
culture, using Vesicular Stomatitis virus and NIH, Ga23-902-530 Hu
IFN-α standard. Double tests had been prepared. The activity of five
separate samples was measured, four of which had the value of 1 ⋅ 105,
and one of ~1.6 ⋅ 105 IU/mg. Compared with the activity of reference
lyophilized HSA-IFN-α (the starting material in the HSA-IFN-α core-
shell NP preparations) of ~1.63 to 1.92 ⋅ 105 IU/mg, it can be estab-
lished that the efficiency of the nanocapsulation is highly effective and
the activity of IFN-α is retained.
4.5. In vitro dissolution tests
HSA-IFN-α core-shell NPs have been used for release kinetics ex-
periments in vitro. The release kinetics results obtained this way are
presented in Fig. 12 for a nanoparticle preparation. The standard de-
viation in the first 4 days were lower than 5.2%. The highest standard
deviation was 8.7% on the 6 day. The total amount of IFN-α was dis-
solved from HSA-IFN-α core-shell NPs after 6 day (Fig. 12). The fol-
lowing mathematical models were evaluated considering the dissolu-
tion profiles of the samples: Korsmeyer-Peppas, and first-order. The
Table 2 shows the fitting results with these dissolution models.Fig. 13.
In the cases of first order model (Eq. (3)) the correlation coefficients
Fig. 7. Changes in the particle size with build-up of subsequent polyelectrolyte
layers on the bare HSA NP surface as measured by DLS and analysed according
to the number-distribution method.
Fig. 8. Determination of the zeta potential of the corresponding types of HSA
and core-shell HSA NPs.
Fig. 9. DSC results of lyophilized HSA, precipitated HSA and the HSA-IFN-α
core-shell NPs.
Fig. 10. The x-ray diffraction of lyophilized samples of original HSA, pre-
cipitated HSA and HSA-IFN-α core-shell NPs. The scattering function of the
crystalline Na2SO4 used for precipitation is added for reference.
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were lower than in case of Korsmeyer-Peppas model. The values ob-
tained during the fitting in the software were outside the expected
range, therefore this model can not be applied in this case. In the case of
Korsmeyer Peppas model (Eq. (4)) the k was 1.4007; and the n was
0.8742. The correlation coefficient (R2) was 0.9947. The Korsmeyer–-
Peppas model was found to be the most suitable for the fitting of the
drug dissolution curves in the majority of the cases, where not only
diffusion but also erosion was involved in the drug release (Table 2). In
our study, the release exponent (n) was 0.5 < n < 0.89, and the dif-
fusion mechanism was therefore anomalous; the drug transport me-
chanism was non-Fickian diffusion. This indicated the coupling of
erosion and diffusion mechanisms, leading to drug release controlled by
multiple processes.
4.6. Results of the in vivo study
The IFN-α concentration values provided relatively constant IFN-α
level during the 10 days of the experiment (Fig. 13.). In addition, Egi-
feron is not a sustained release formulation, and the extremely high
IFN-α level (90 pg/mL) is reached within one day. With application of
Graph Pad Prism software the AUC and AUMC values were calculated.
The AUC was 1179 h (pg/ml) and the AUMC 15390 h2 (pg/ml) and the
MRT 13.05 h. In Table 3, the calculated values from our experiments
and the values from the literature (Roferon A) were compared. In the
case of HSA-IFN-α core-shell NPs there were no cmax value well defined.
This NP can ensure constant IFN-α blood level.
5. Conclusions
Sustained release formulations are designed according to a variety
of techniques, which are mostly expensive, complicated, requiring
serious instrumentation, and, may not be fully adequate for the aim of
preserving the activity of the agent, just to mention a few common
difficulties. We present in this paper a novel method of core-shell na-
noparticle preparation for protein drugs or protein-bound active com-
pounds, which provides a relatively easy and inexpensive way of the
formulation of sustained release products. Extension to non-protein
based drugs is also conceivable. The new particle is formed by salt-
precipitation of IFN-α containing HSA to 10 nm sized particles, and
building up three polyelectrolyte layers on the particle surface in L-b-L
strategy. The anionic polyelectrolyte is PSS and the cationic one is Chit.
We have demonstrated that the particle size is in the nano-size range,
and that the outer surface is negatively charged. IFN-α activity tests
Fig. 11. The TEM pictures of HSA-IFN-α core-shell NPs with different focusing.
Fig. 12. HSA release from HSA-IFN-α core-shell NPs, measured in pH=7.4
PBS buffer at 36 °C in Hanson cell.
Table 2
The fitted dissolution kinetic models and the correlation coefficients.
Sorted List n k R2
Korsmeyer–Peppas (Eq. (1)) 0.8742 1.4007 0.9947
First Order (Eq. (2)) 1 0.0032 0.9938
Fig. 13. Comparison of the blood IFN-α level of rabbits after subcutan ad-
ministration of core-shell nanoparticle formulation and of the Egiferon sub-
cutan injection.
Table 3
The kinetic parameters of human interferon-α in rabbit (t1/2: elimination half-
life time; Cl: clearance; MRT: mean residence time).
Human (Roferon A) Rabbit (Core-shell HSA-IFN NP)
tmax (h) 7.3 6
t1/2 (h) (Eq. (4)) 5.01 9.04
Cl (ml/min/kg) 2.79 2.61
MRT (h) (Eq. (3)) 7.63 13.05
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reveal that the formulation did not decrease IFN-α activity. Both in
vitro and in vivo release kinetics experiments have proven slow active
agent dissolution from the formulation.
After the establishment of the successful preparation technology,
further improvements should be carried out in order to provide a safe
formulation of the core-shell NPs. Biocompatible anionic polyelec-
trolytes with fully dissociated charge groups should be tested for re-
placing PSS. Alternatives could also be tested for replacement of the
biocompatible Chit in order to vary the rate of IFN-α release. Scaling up
of the technology to industrial size presents an additional challenge.
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